Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2003

View Archived Issues

LY-510929 characterized in animal models as a treatment for type 2 diabetes and dyslipidemia

Preclinical activity of LM-4156, a balanced activator of PPARalpha and PPARgamma

11-Beta-HSD1 inhibitors presented by Biovitrum researchers

Dompe patents novel inhibitors of IL-8 and GROalpha-induced chemotaxis

New aP2 or dual aP2/k-FABP inhibitors and their use disclosed by BMS scientists

Novel factor Xa inhibitors in early development at GSK

Bayer claims the preparation and use of synthetic andrimide and moiramide B analogues

Neurogen patents covers new GABA-A receptor ligands

ORL1 receptor agonists and their use as antitussives, analgesics, anxiolytics, etc.

Preclinical data on ISIS-113715, a PTP1B antisense oligonucleotide for the treatment of diabetes

OSI recovers North American rights to market Gelclair for oncology

Extended-release alfuzosin approved for BPH

New phase II study evaluates Dacogen in combination with Gleevec for CML

Inhibition of p38 MAP kinase effective for prevention and treatment of diabetes in NOD mice

Xyotax granted fast track status for advanced NSCLC

Zavesca approved in Israel for Gaucher's disease

Adventrx chosen as new corporate identity for Biokeys

Bile acid sequestrant from BTG, ready for phase III trials, available for licensing

Vaxim discovers SARS antigenic peptide

Health-related quality-of-life results from phase III Riquent trial

Cardiovascular agent offered for licensing by Biorex

EN-101 enters extension study for myasthenia gravis

Clinical hold on Enzo Biochem's HIV gene therapy trials lifted

NS-2330 enters further phase II study in Parkinson's disease

Trisenox NDA submitted in Japan

Pipeline update at Celltech Group

Preclinical antitumor activity of AP-23573 characterized at ASCO meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...